GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » PS Ratio

Ligand Pharmaceuticals (Ligand Pharmaceuticals) PS Ratio : 9.62 (As of Apr. 26, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ligand Pharmaceuticals's share price is $71.31. Ligand Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.42. Hence, Ligand Pharmaceuticals's PS Ratio for today is 9.62.

The historical rank and industry rank for Ligand Pharmaceuticals's PS Ratio or its related term are showing as below:

LGND' s PS Ratio Range Over the Past 10 Years
Min: 3.72   Med: 10.94   Max: 20.64
Current: 9.63

During the past 13 years, Ligand Pharmaceuticals's highest PS Ratio was 20.64. The lowest was 3.72. And the median was 10.94.

LGND's PS Ratio is ranked worse than
52.47% of 993 companies
in the Biotechnology industry
Industry Median: 8.92 vs LGND: 9.63

Ligand Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $1.59. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.42.

Warning Sign:

Ligand Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Ligand Pharmaceuticals was -36.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -8.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 16.30% per year.

During the past 13 years, Ligand Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 91.00% per year. The lowest was -65.00% per year. And the median was 10.30% per year.

Back to Basics: PS Ratio


Ligand Pharmaceuticals PS Ratio Historical Data

The historical data trend for Ligand Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals PS Ratio Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.68 6.38 6.88 5.74 9.66

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.74 6.22 6.95 6.80 9.66

Competitive Comparison of Ligand Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Ligand Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's PS Ratio falls into.



Ligand Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ligand Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=71.31/7.415
=9.62

Ligand Pharmaceuticals's Share Price of today is $71.31.
Ligand Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ligand Pharmaceuticals  (NAS:LGND) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ligand Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282